A sleep medicine was tested in severe sleep apnea without worsening breathing
In short: People with severe obstructive sleep apnea often also struggle to sleep. A small crossover trial tested whether daridorexant, an insomnia medicine, would disturb nighttime breathing. It did not, and sleep improved. The deeper layer explains what was measured, what the results mean and where the evidence is still thin.
Obstructive sleep apnea is a condition in which the airway repeatedly narrows or collapses during sleep, interrupting breathing and lowering blood oxygen. Many people with it also report insomnia-related symptoms, and the safety of insomnia medicines in this group has been unclear. Daridorexant is a dual orexin receptor antagonist used for insomnia. Earlier work suggested it did not harm breathing in people with mild or moderate apnea, so researchers asked whether the same held at a more severe level. The study was a randomized, double-blind, placebo-controlled crossover trial at a single sleep centre, with 16 adults who had severe apnea but no insomnia. Each person took 50 mg of daridorexant or a placebo every evening for five days, then switched. The main measures were the apnea/hypopnea index, which counts breathing events per hour, and oxygen saturation during sleep. The baseline apnea index averaged about 51 events per hour.
The authors set a rise of 10 or more events per hour, or a fall of 2 percentage points or more in oxygen, as the threshold for a clinically meaningful harm. Neither threshold was reached. The difference in breathing events was -3.7 per hour, and the difference in oxygen was -0.12 percent, with confidence limits that ruled out meaningful harm. Daridorexant increased total sleep time by about 32 minutes compared with placebo, along with a shorter time to fall into persistent sleep. Only four adverse events were reported, all mild and none linked to breathing. The authors are cautious. Sixteen participants and five nights of dosing make a small and short test, and the findings describe severe apnea without insomnia, not the wider population.
A related meta-analysis of daridorexant in insomnia found that its benefits depend on dose and time. Across trials with nearly 2,900 patients, the drug outperformed placebo early on, with advantages reported at one month and the 25 mg dose still showing benefit at three months. The same analysis linked the 25 mg dose to a higher risk of certain adverse events of special interest, while overall tolerability was described as relatively good.
The broader evidence on its size of effect is also debated. A large network meta-analysis found its effect against placebo to be small, and it did not conclude that daridorexant offers a clear overall benefit for insomnia, even though benzodiazepines and Z-drugs showed larger effects in that comparison. For this reason, orexin receptor antagonists are not generally used as first-line treatments.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Daridorexant in severe obstructive sleep apnea: effects on sleep-disordered breathing and sleep.
- Also: The "efficacy window" phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis.
- Also: Daridorexant
To cite this card, link to https://intellectplus.co.uk/app/health-daridorexant.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health, medicine and disease · More in Health · Latest · A–Z · All topics